Worlds (WDDD) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-24115
Entity Registrant Name	WORLDS INC.
Entity Central Index Key	0000001961
Entity Tax Identification Number	22-1848316
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11 Royal Road
Entity Address, City or Town	Brookline
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02445
City Area Code	(617)
Local Phone Number	725-8900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		57,112,506

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 36,973	$ 44,421
Other Assets	8,222	8,222
Total Current Assets	45,195	52,643
Convertible Note Receivable	200,000	200,000
Accrued interest receivable	38,500	31,461
Total assets	283,695	284,104
Current Liabilities
Accounts payable	827,910	975,255
Accrued expenses	1,559,420	1,546,480
Notes payable exceeding statute of limitations	773,279	773,279
Total Current Liabilities	3,160,609	3,295,014
Total Liabilities	3,160,609	3,295,014
Common stock (Par value $0.001 authorized 250,000,000 shares, issued and outstanding 57,112,506 at June 30, 2022 and December 31, 2021	57,113	57,113
Additional paid in capital	42,372,656	41,513,730
Common stock-warrants	1,206,913	1,206,913
Accumulated deficit	(46,513,596)	(45,788,666)
Total stockholders deficit	(2,876,914)	(3,010,910)
Total Liabilities and stockholders' deficit	$ 283,695	$ 284,104

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares outstanding	57,112,506	57,112,506
Common stock, shares issued	57,112,506	57,112,506

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue
Total Revenue
Cost and Expenses
Cost of Revenue
Gross Profit/(Loss)
Option expense	15,904	51,692	821,296	109,874
Selling, General & Admin.	140,905	566,137	377,530	1,319,571
Salaries and related	51,755	50,709	101,649	104,065
Operating loss	(208,563)	(668,538)	(1,300,475)	(1,533,510)
Other Income (Expense)
Gain on sale of marketable securities	238,767	433,735	606,136	864,926
Settlement of litigation		315,000		315,000
Loss on Issuance of shares for services				(8,685)
Interest income	3,539	3,539	7,039	7,039
Interest expense	(18,919)	(18,919)	(37,630)	(37,810)
Net Income/(Loss)	$ 14,823	$ 64,817	$ (724,930)	$ (393,040)
Weighted Average Loss per share, basic and diluted			$ (0.01)	$ (0.01)
Weighted Average Common Shares Outstanding, basic and diluted	57,112,506	57,112,506	57,112,506	57,031,920

Statement of Stockholders' Defi

Statement of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Warrant [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 56,815	$ 41,240,880	$ 1,206,913	$ (45,174,496)	$ (2,669,888)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	56,814,833
Fair value of stock options		109,874			109,874
Common stock issued for settlement of accounts payable - related party	$ 298	70,512			70,810
Common stock issued for settlement of accounts payable - related party - shares	297,673
Gain on forgiveness of accounts payable - related party		16,401			16,401
Imputed Interest		37,810			37,810
Net Loss				(393,040)	(393,040)
Ending balance, value at Jun. 30, 2021	$ 57,113	41,475,477	1,206,913	(45,567,536)	(2,828,033)
Shares, Outstanding, Ending Balance at Jun. 30, 2021	57,112,506
Beginning balance, value at Dec. 31, 2021	$ 57,113	41,513,730	1,206,913	(45,788,666)	(3,010,910)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	57,112,506
Fair value of stock options		821,296			821,296
Imputed Interest		37,630			37,630
Net Loss				(724,930)	(724,930)
Ending balance, value at Jun. 30, 2022	$ 57,113	$ 42,372,656	$ 1,206,913	$ (46,513,596)	$ (2,876,914)
Shares, Outstanding, Ending Balance at Jun. 30, 2022	57,112,506

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (724,930)	$ (393,040)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of stock options issued for services	821,296	109,874
Loss on shares issued for settlement of accounts payable - related party		8,685
Realized gain on sale of marketable securities	(606,136)	(864,926)
Imputed interest	37,630	37,810
Changes in assets and liabilities
Accounts payable and accrued expenses	(134,405)	416,237
Net cash (used in) operating activities:	(606,544)	(685,359)
Cash flows from financing activities
Cash received from sale of marketable securities	606,136	864,926
Accrued interest receivable - related party	(7,039)	(7,039)
Net cash provided by financing activities	599,097	857,887
Net increase/(decrease) in cash and cash equivalents	(7,448)	172,528
Cash and cash equivalents, including restricted, beginning of year	44,421	474,587
Cash and cash equivalents, including restricted, end of period	36,973	647,115
Cash paid during the period for:
Interest
Income taxes
Non-cash financing activities
Shares issued for settlement of accounts payable - related party		62,125
Gain on forgiveness of accounts payable - related party		$ 16,401

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 1 – GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $ 2,876,914 2,876,914 606,544 Management believes that the actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern, although no assurance can be given that the Company will be successful.

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES	NOTE 2 – DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES Description of Business On May 16, 2011, the Company transferred, through a spin-off to its then wholly owned subsidiary, Worlds Online Inc. (currently called MariMed Inc.), the majority of its operations and related operational assets. The Company retained its patent portfolio and is looking to expand on its legacy celebrity worlds and its collection of non-fungible tokens. Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). The Company has incurred significant losses since its inception and has had minimal revenues from operations. The Company will require substantial additional funds for its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. There can be no assurance that the Company will be able to obtain the substantial additional capital resources to pursue its business plan or that any assumptions relating to its business plan will prove to be accurate. The Company has not been able to generate sufficient revenue or obtain sufficient financing which has had a material adverse effect on the Company, including requiring the Company to reduce operations. As the Company has focused its attention historically on increasing its patent portfolio and enforcing it, and more recently on its expansion of its legacy celebrity worlds and its collection of non-fungible tokens, the Company has been operating at a reduced capacity, with only one employee and using consultants to perform any additional work that may be required. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Cash and Cash Equivalents Cash and cash equivalents include highly liquid money market instruments, which have original maturities of three months or less at the time of purchase. Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606. There was no impact in adopting ASC 606 as the Company has no revenue at this time. In the second quarter of 2011, the Company spun off its online businesses to MariMed Inc. The Company’s sources of revenue after the spinoff was expected to be from sublicenses of the patented technology by Worlds Online and any revenue that may be generated from enforcing its patents. Commencing in the first half of 2022, the Company expects that its revenues will come from its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. The Company recognizes revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Research and Development Costs Research and development costs are charged to operations as incurred. Property and Equipment Property and equipment are stated at cost. Depreciation is provided on a straight line basis over the estimated useful lives of the assets ranging from three to five years. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Maintenance and repairs are charged to expense in the period incurred. Impairment of Long Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with section 360-10-15 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for disclosures about Impairment or Disposal of Long-Lived Assets. Disclosure requires recognition of impairment of long-lived assets in the event the net book value of such assets exceeds its expected cash flows. If so, it is considered to be impaired and is written down to fair value, which is determined based on either discounted future cash flows or appraised values. The Company adopted the statement on inception. No impairments of these types of assets were recognized during the first quarters of 2022 and 2021. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method following the guidance set forth in section 718-10 of the FASB ASC for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Income Taxes The Company accounts for income taxes under Section 740-10-30 of the FASB ASC. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% Notes Payable The Company has $ 773,279 Comprehensive Income (Loss) The Company reports comprehensive income and its components following guidance set forth by section 220-10 of the FASB ASC which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. There were no items of comprehensive income (loss) applicable to the Company during the period covered in the financial statements. Loss Per Share Net loss per common share is computed pursuant to section 260-10-45 of the FASB ASC. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. As of June 30, 2022, there were 27,620,000 4,380,000 11,720,000 4,380,000 Commitments and Contingencies The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. During 2000 the Company was involved in a lawsuit relating to unpaid consulting services. In April, 2001 a judgment against the Company was rendered for approximately $ 205,000 205,000 Risk and Uncertainties The Company is subject to risks common to companies in the technology industries, including, but not limited to, litigation, development of new technological innovations and dependence on key personnel. Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements. Uncertain Tax Positions The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the year ended December 31, 2021. Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: • Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. • Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company’s financial assets and liabilities, such as cash, other receivables, accounts payable & accrued expenses, due to related party, notes payable and notes payables, approximate their fair values because of the short maturity of these instruments. The Company's convertible notes payable are measured at amortized cost. Warrant and option expense was measured by using level 3 valuation. Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. The Company accounts for stock-based compensation for employees and directors in accordance with Accounting Standards Codification 718, Compensation (“ASC 718”) as issued by the FASB. ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in Accounting Standards Update (“ASU”) 2018-07. In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 3 - NOTES PAYABLE Notes payable at June 30, 2022 consist of the following: Unsecured note payable bearing 8% interest, entire balance of principal and unpaid interest due on demand $ 124,230 Unsecured note payable bearing 10% interest, entire balance of principal and unpaid interest due on demand $ 649,049 Total notes $ 773,279 2022 $ 773,279 2023 $ -0- 2024 $ -0- 2025 $ -0- 2026 $ -0- $ 773,279 The Company imputed interest of $ 18,919

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
EQUITY	NOTE 4 - EQUITY All common stock numbers and exercise prices in this Note are reflected on a post reverse split ( 5 to 1 During the six months ended June 30, 2022, the Company issued 15,900,000 900,000 As consideration for the IP in the Asset Purchase Agreement between the Company and Mr. Kidrin, Mr Kidrin was granted 15,000,000 $0.07 $751,744 1.35% 0% 174% $0.07 $0.07 3 The active directors of the Company received 300,000 31,108 1.37 0 142 $0.05 $0.05 5 six The active directors of the Company had their existing options repriced and the terms extended another 5 900,000 $38,444 1.90% 0% 153% $0.08 $0.08 5 During the six months ended June 30, 2021, the Company issued 297,673 $70,810 $8,685 During the six months ended June 30, 2021, the Company recorded an option expense of $ 109,874 During the six months ended June 30, 2022, the Company recorded an option expense of $ 821,296 Stock Warrants and Options Stock warrants/options outstanding and exercisable on June 30, 2022 are as follows Exercise Price per Share Shares Under Option/warrant Remaining Life in Years Outstanding $ 0.325 3,400,000 0.58 $ 0.15 5,220,000 0 .25 $ 0.15 580,000 0.50 $ 0.05 200,000 0.50 $ 0.30 200,000 0.50 $ 0.25 5,000,000 1.16 $ 0.24 200,000 1.16 $ 0.07 15,000,000 2.55 $ 0.27 300,000 3.45 $ 0.3 100,000 3.50 $ 0.05 900,000 4.50 $ 0.08 900,000 4.63 Total 32,000,000 Exercisable $ 0.325 3,400,000 0.58 $ 0.15 5,220,000 0.25 $ 0.15 580,000 0.50 $ 0.05 200,000 0.50 $ 0.30 200,000 0.50 $ 0.25 5,000,000 1.16 $ 0.24 200,000 1.16 $ 0.07 15,000,000 2.55 $ 0.27 300,000 3.45 $ 0.03 100,000 3.50 $ 0.08 900,000 4.63 Total 31,100,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 5 - COMMITMENTS AND CONTINGENCIES The Company is committed to an employment agreement with its President and CEO, Thom Kidrin. The agreement, dated as of August 28, 2018, is for five one $200,000 10% $500 2.5% $75,000 150% 200% $100,000 201% 250% $200,000 251% 5% $10,000 5 million $0.25 2 million 1.5 million 1.5 million 2 million 2.99 12

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 - RELATED PARTY TRANSACTIONS During the six months ended June 30, 2022, the Company entered into an asset purchase agreement with Thom Kidrin the CEO of the Company. The Company purchased certain IP which was transferred to Worlds Online Inc., now called MariMed Inc.. Mr. Kidrin received the IP as part of a settlement agreement he signed with MariMed Inc. The purchase price was 15 0.07 three During the six months ended June 30, 2021, the Company issued 297,673 70,810 8,685 During the six months ended June 30, 2021, the Company recorded a gain on forgiveness of accounts payable related party due to the Company’s CFO in the amount of $ 16,401 The balance in the accrued expense attributable to related parties is $ 46,438 33,899 See note 9 for a discussion on the convertible note receivable from the related party.

PATENTS

PATENTS	6 Months Ended
	Jun. 30, 2022
Revenue Recognition and Deferred Revenue [Abstract]
PATENTS	NOTE 7 - PATENTS Worlds Inc. currently has nine 6,219,045 7,181,690 7,493,558 7,945,856 8,082,501 8,145,998 8,161,383 8,407,592 8,640,028

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 8 – ACCRUED EXPENSES Accrued expenses is comprised of (i) $46,438 $205,000 $1,305,009 $2,972

CONVERTIBLE NOTE RECEIVABLE _ R

CONVERTIBLE NOTE RECEIVABLE – RELATED PARTY	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
CONVERTIBLE NOTE RECEIVABLE – RELATED PARTY	NOTE 9 – CONVERTIBLE NOTE RECEIVABLE – RELATED PARTY The Company made an investment in the form of a convertible note in the amount of $200,000 7 2 one million $0.05 $38,500 29,303,395 $0.008139 1% During the six months ended June 30, 2022, the Company earned $ 7,039 During the six months ended June 30, 2021, the Company earned $ 7,039

SALE OF MARKETABLE SECURITIES

SALE OF MARKETABLE SECURITIES	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
SALE OF MARKETABLE SECURITIES	NOTE 10 – SALE OF MARKETABLE SECURITIES When Worlds Inc. spun off Worlds Online Inc. in January 2011, the Company retained 5,936,115 0 During the six months ended June 30, 2022 the Company generated net cash of $ 606,136 900,000 0.70 During the six months ended June 30, 2021 the Company generated net cash of $ 864,926 1,095,000 100,000 0.79 As of June 30, 2022, the Company still owns approximately 850,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any additional recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements.

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business On May 16, 2011, the Company transferred, through a spin-off to its then wholly owned subsidiary, Worlds Online Inc. (currently called MariMed Inc.), the majority of its operations and related operational assets. The Company retained its patent portfolio and is looking to expand on its legacy celebrity worlds and its collection of non-fungible tokens.
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). The Company has incurred significant losses since its inception and has had minimal revenues from operations. The Company will require substantial additional funds for its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. There can be no assurance that the Company will be able to obtain the substantial additional capital resources to pursue its business plan or that any assumptions relating to its business plan will prove to be accurate. The Company has not been able to generate sufficient revenue or obtain sufficient financing which has had a material adverse effect on the Company, including requiring the Company to reduce operations. As the Company has focused its attention historically on increasing its patent portfolio and enforcing it, and more recently on its expansion of its legacy celebrity worlds and its collection of non-fungible tokens, the Company has been operating at a reduced capacity, with only one employee and using consultants to perform any additional work that may be required.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include highly liquid money market instruments, which have original maturities of three months or less at the time of purchase.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606. There was no impact in adopting ASC 606 as the Company has no revenue at this time. In the second quarter of 2011, the Company spun off its online businesses to MariMed Inc. The Company’s sources of revenue after the spinoff was expected to be from sublicenses of the patented technology by Worlds Online and any revenue that may be generated from enforcing its patents. Commencing in the first half of 2022, the Company expects that its revenues will come from its expansion of its legacy celebrity worlds and its collection of non-fungible tokens. The Company recognizes revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.
Research and Development Costs	Research and Development Costs Research and development costs are charged to operations as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is provided on a straight line basis over the estimated useful lives of the assets ranging from three to five years. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Maintenance and repairs are charged to expense in the period incurred.
Impairment of Long Lived Assets	Impairment of Long Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with section 360-10-15 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for disclosures about Impairment or Disposal of Long-Lived Assets. Disclosure requires recognition of impairment of long-lived assets in the event the net book value of such assets exceeds its expected cash flows. If so, it is considered to be impaired and is written down to fair value, which is determined based on either discounted future cash flows or appraised values. The Company adopted the statement on inception. No impairments of these types of assets were recognized during the first quarters of 2022 and 2021.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method following the guidance set forth in section 718-10 of the FASB ASC for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.
Income Taxes	Income Taxes The Company accounts for income taxes under Section 740-10-30 of the FASB ASC. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50%
Notes Payable	Notes Payable The Company has $ 773,279
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company reports comprehensive income and its components following guidance set forth by section 220-10 of the FASB ASC which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. There were no items of comprehensive income (loss) applicable to the Company during the period covered in the financial statements.
Loss Per Share	Loss Per Share Net loss per common share is computed pursuant to section 260-10-45 of the FASB ASC. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. As of June 30, 2022, there were 27,620,000 4,380,000 11,720,000 4,380,000
Commitments and Contingencies	Commitments and Contingencies The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. During 2000 the Company was involved in a lawsuit relating to unpaid consulting services. In April, 2001 a judgment against the Company was rendered for approximately $ 205,000 205,000
Risk and Uncertainties	Risk and Uncertainties The Company is subject to risks common to companies in the technology industries, including, but not limited to, litigation, development of new technological innovations and dependence on key personnel.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements. Uncertain Tax Positions The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the year ended December 31, 2021.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: • Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. • Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company’s financial assets and liabilities, such as cash, other receivables, accounts payable & accrued expenses, due to related party, notes payable and notes payables, approximate their fair values because of the short maturity of these instruments. The Company's convertible notes payable are measured at amortized cost. Warrant and option expense was measured by using level 3 valuation.
Embedded Conversion Features	Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations. The Company accounts for stock-based compensation for employees and directors in accordance with Accounting Standards Codification 718, Compensation (“ASC 718”) as issued by the FASB. ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in Accounting Standards Update (“ASU”) 2018-07. In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Notes payable at June 30, 2022 consist of the following: Unsecured note payable bearing 8% interest, entire balance of principal and unpaid interest due on demand $ 124,230 Unsecured note payable bearing 10% interest, entire balance of principal and unpaid interest due on demand $ 649,049 Total notes $ 773,279 2022 $ 773,279 2023 $ -0- 2024 $ -0- 2025 $ -0- 2026 $ -0- $ 773,279

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stock Warrants and Options	Stock Warrants and Options Stock warrants/options outstanding and exercisable on June 30, 2022 are as follows Exercise Price per Share Shares Under Option/warrant Remaining Life in Years Outstanding $ 0.325 3,400,000 0.58 $ 0.15 5,220,000 0 .25 $ 0.15 580,000 0.50 $ 0.05 200,000 0.50 $ 0.30 200,000 0.50 $ 0.25 5,000,000 1.16 $ 0.24 200,000 1.16 $ 0.07 15,000,000 2.55 $ 0.27 300,000 3.45 $ 0.3 100,000 3.50 $ 0.05 900,000 4.50 $ 0.08 900,000 4.63 Total 32,000,000 Exercisable $ 0.325 3,400,000 0.58 $ 0.15 5,220,000 0.25 $ 0.15 580,000 0.50 $ 0.05 200,000 0.50 $ 0.30 200,000 0.50 $ 0.25 5,000,000 1.16 $ 0.24 200,000 1.16 $ 0.07 15,000,000 2.55 $ 0.27 300,000 3.45 $ 0.03 100,000 3.50 $ 0.08 900,000 4.63 Total 31,100,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficiency	$ 2,876,914
Stockholders deficiency	2,876,914
Cash in operations	$ 606,544

DESCRIPTION OF BUSINESS AND S_3

DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Jun. 30, 2021	Apr. 30, 2001	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Tax benefit likelihood			50%
Short term notes outstanding			$ 773,279	$ 773,279
Options outstanding	11,720,000		27,620,000
Warrants outstanding	4,380,000
Warrants outstanding whose effect is anti-dilutive	4,380,000
Litigation Settlement, Amount Awarded to Other Party		$ 205,000
Estimated Litigation Liability			$ 205,000	$ 205,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Unsecured note payable bearing 8% interest, entire balance of principal and unpaid interest due on demand	$ 124,230,000
Unsecured note payable bearing 10% interest, entire balance of principal and unpaid interest due on demand	649,049,000
Total notes	773,279	$ 773,279
2022	773,279
2023	0
2024	0
2025	0
2026	$ 0

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)	Jun. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Imputed interest	$ 18,919

Stock Warrants and Options (Det

Stock Warrants and Options (Details)	Jun. 30, 2022 $ / shares shares
Outstanding 1
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.325
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,400,000
Remaining life in years	0.58
Outstanding 2
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.15
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,220,000
Remaining life in years	0
Outstanding 3
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.15
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	580,000
Remaining life in years	0.50
Outstanding 4
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	0.50
Outstanding 5
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.30
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	0.50
Outstanding 6
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.25
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,000,000
Remaining life in years	1.16
Outstanding 7
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.24
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	1.16
Outstanding 8
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.07
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	15,000,000
Remaining life in years	2.55
Outstanding 9
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.27
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	300,000
Remaining life in years	3.45
Outstanding 10 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	100,000
Remaining life in years	3.50
Outstanding 11 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	900,000
Remaining life in years	4.50
Outstanding 12 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.08
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	900,000
Remaining life in years	4.63
Total Outstanding [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Total outstanding	32,000,000
Exercisable 1
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.325
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,400,000
Remaining life in years	0.58
Exercisable 2
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.15
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,220,000
Remaining life in years	0.25
Exercisable 3
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.15
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	580,000
Remaining life in years	0.50
Exercisable 4
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	0.50
Exercisable 5
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.30
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	0.50
Exercisable 6
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.25
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,000,000
Remaining life in years	1.16
Exercisable 7
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.24
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	200,000
Remaining life in years	1.16
Exercisable 8 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.07
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	15,000,000
Remaining life in years	2.55
Exercisable 9 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.27
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	300,000
Remaining life in years	3.45
Exercisable 10 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.03
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	100,000
Remaining life in years	3.50
Exercisable 11 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.08
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	900,000
Remaining life in years	4.63
Total Exercisable [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Total exercisable	31,100,000

EQUITY (Details Narrative)

EQUITY (Details Narrative)		3 Months Ended		6 Months Ended
	Feb. 10, 2018	Jun. 30, 2022 USD ($) yr Interger $ / shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) yr Interger $ / shares shares	Jun. 30, 2021 USD ($) shares	Feb. 16, 2022 shares	Jan. 03, 2022 shares
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Post reverse split	5
Options re-issued to directors | shares				15,900,000
Exercise price | $ / shares				$ 0.05
Risk free interest				137%
Dividend yield				0%
Volatility				14,200%
Market price | $ / shares		$ 0.05		$ 0.05
Expected life | yr		5		5
Directors options received | shares							300,000
Recorded option expense for directors options | $				$ 31,108
Months option vest | Interger		6		6
Total number of options repriced | shares						900,000
Options expense for directors options | $				$ 38,444
Stock Issued During Period, Shares, Other | shares					297,673
Value of shares issued | $					$ 70,810
Loss on shares issued | $					8,685
Recorded an option expense | $		$ 15,904	$ 51,692	$ 821,296	$ 109,874
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options re-issued to directors | shares				900,000
Options granted | shares				15,000,000
Exercise price | $ / shares				$ 0.07
Recorded option expense for officer options | $				$ 751,744
Risk free interest				1.35%
Dividend yield				0%
Volatility				174%
Market price | $ / shares		$ 0.07		$ 0.07
Expected life | yr		3		3
Director [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Risk free interest				1.90%
Dividend yield				0%
Volatility				153%
Market price | $ / shares		$ 0.08		$ 0.08
Expected life | yr		5		5
Director Terms Extended | yr		5		5

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Aug. 29, 2018 shares	Aug. 28, 2020 shares	Aug. 28, 2019 shares	Aug. 28, 2018 USD ($) yr Interger $ / shares shares
Employee contract terms | yr				5
Employment renewal option | yr				1
Base salary				$ 200,000
Annual base salary increase				10%
Car allowance				$ 500
Annual bonus				0.025
Additional bonus				$ 75,000
Pretax income, lower | $ / shares				$ 1.50
Pretax income, higher | $ / shares				$ 200
Additional bonus limit				0.05
Life insurance premiums				$ 10,000
Number of options allowed to purchase | shares	5,000,000
Options purchase price | $ / shares				$ 0.25
Number of vested options | shares				2,000,000
Number of vested options | shares		1,500,000	1,500,000
Death benefit				$ 2,000,000
Payment amount times base amount				2.99
Restrictive convenants amount | Interger				12
Additional bonus 1
Additional bonus				$ 100,000
Pretax income, lower | $ / shares				$ 201
Pretax income, higher | $ / shares				$ 250
Additional bonus 2
Additional bonus				$ 200,000
Pretax income, lower | $ / shares				$ 251

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	3 Months Ended	6 Months Ended
	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($) yr $ / shares shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Price per share | $ / shares		$ 0.05
Shares issued of common stock | shares			297,673
Value of share issued	$ 70,810
Loss on issuance of common stock			$ 8,685
Forgiveness of accounts payable			$ 16,401
balance in the accrued expense		$ 46,438		$ 33,899
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options to purchase common stock | shares		15
Price per share | $ / shares		$ 0.07
Years for options | yr		3

PATENTS (Details Narrative)

PATENTS (Details Narrative)	6 Months Ended
	Jun. 30, 2022 Interger
Revenue Recognition and Deferred Revenue [Abstract]
Patents	9
Patent number one	6,219,045
Patent number two	7,181,690
Patent number three	7,493,558
Patent number four	7,945,856
Patent number five	8,082,501
Patent number six	8,145,998
Patent number seven	8,161,383
Patent number eight	8,407,592
Patent number nine	8,640,028

ACCRUED EXPENSES (Details Narra

ACCRUED EXPENSES (Details Narrative) - USD ($)	1 Months Ended
	Apr. 30, 2001	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Owed to related parties		$ 46,438	$ 33,899
Related to a judgment	$ 205,000
Old accruals		1,305,009
Accruals for recurring operating expenses balance		$ 2,972

CONVERTIBLE NOTE RECEIVABLE __2

CONVERTIBLE NOTE RECEIVABLE – RELATED PARTY (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($) yr $ / shares shares	Jun. 30, 2021 USD ($)
Receivables [Abstract]
Convertible note to CASH	$ 200,000
Convertible note annual interest	700%
Maturity time of Note | yr	2
Warrants for note extension | shares	1,000,000
Purchase price for common stock for warrants | $ / shares	$ 0.05
Amount of convertible note and accrued interest	$ 38,500
Number of shares if noted converted | shares	29,303,395
Conversion price if noted converted | $ / shares	$ 0.008139
Ownership if note converted	1%
Interest on note	$ 7,039	$ 7,039

SALE OF MARKETABLE SECURITIES (

SALE OF MARKETABLE SECURITIES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2011
Investments, Debt and Equity Securities [Abstract]
Number of reatined shares from spin off						5,936,115
Retained shares value				$ 0
Generated net cash from sale		$ 238,767	$ 433,735	$ 606,136	$ 864,926
Sale of common stock	100,000			900,000	1,095,000
Average price per share		$ 0.70	$ 0.79	$ 0.70	$ 0.79
Shares own of MariMed Inc		$ 850,000		$ 850,000